Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

208
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
208
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

54
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
54
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

77
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
77
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

37
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
37
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

68
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
68
Pharmacovigilance01:19

Pharmacovigilance

763
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
763

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mapping the Parkinson's pandemic: Unveiling and addressing the global burden.

Journal of Parkinson's disease·2026
Same author

<i>APOE</i>-associated disease risk and sex-specific effects in Egyptian Alzheimer's disease: an exploratory study.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Increased polysaccharide molecular interaction improves foam template oil absorption behavior of egg white protein oleogel.

Food chemistry·2026
Same author

Placental Growth Factor Associated with Perinatal Outcomes: An Urban-Rural Analysis in Western Canada.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Outcome-specific risk factors challenge universal dementia prevention priorities: Findings from the Egyptian Dementia Network Registry.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Placental Growth Factor and Uterine-Artery Doppler for Prediction of Preeclampsia, Fetal Growth Restriction and Early Preterm Birth.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026

相关实验视频

Updated: May 22, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K

优化老年护理:一个数据驱动的AI模型用于预测老年人使用SHARE数据预测多药风险.

Aliaa A Elhosseiny1, Seif Eldawlatly2, Eman Ramadan3

  • 1Institute of Global Health and Human Ecology (I-GHHE), The American University in Cairo, Cairo, Egypt; Department of Pharmacology and Toxicology, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.

Neuroscience
|May 7, 2025
PubMed
概括
此摘要是机器生成的。

多药性 (PP) 在老年人中正在增加. 机器学习模型可以使用纵向数据预测PP风险,强调心理健康是关键因素.

关键词:
衰老的衰老 衰老的衰老纵向的 纵向的 纵向的机器学习 机器学习多种药房 多种药房预测性的 预测性的分享 分享 分享 分享

更多相关视频

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K

相关实验视频

Last Updated: May 22, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K

科学领域:

  • 老年学与公共卫生
  • 计算医学是一种计算医学.
  • 医疗保健服务研究 医疗服务研究

背景情况:

  • 人口老龄化面临多重疾病,增加医疗保健的复杂性.
  • 多药性 (PP),定义为同时使用超过五种药物,是老年人面临的重大挑战.
  • PP有助于认知和身体功能下降.

研究的目的:

  • 预测50岁以上个体的多药性 (PP) 风险.
  • 用纵向数据分析2,4年和6年间隔的PP趋势.
  • 确定PP风险的关键预测因素.

主要方法:

  • 利用了SHARE研究的数据,重点关注50岁以上的参与者,跨越多个波.
  • 使用LASSO回归来选择PP风险的17个关键预测变量.
  • 通过交叉验证评估了八个机器学习 (ML) 模型,包括分类提升.

主要成果:

  • 多药制药的流行率呈现上升趋势,在研究浪潮中从34.03%增加到39.91%.
  • 确定了社会人口统计学,生活方式,身体/精神健康和病史作为关键PP预测因素.
  • 分类提升ML模型在预测PP风险方面实现了最高的准确性 (高达75.08%) 和回忆 (高达72.83%).

结论:

  • 多药性 (PP) 患病率在老年人中正在上升.
  • 纵向数据与机器学习 (ML) 结合,为PP风险预测提供了一种可行的方法.
  • 心理健康状况是管理和减轻PP的关键因素.